A revolutionary new treatment that will save lives
![](https://cdn.sanity.io/images/dlwec8tx/homepage/75c63e27016527822b87aa1c8465c6374774fc43-8280x6208.jpg?auto=format)
Treatments
Up until now P. vivax malaria most commonly found in Southeast Asia and Latin America has been treated with a 14-day course of treatment for radical cure – many patients never complete the full course of treatment which increases the chance of a relapse. British pharmaceutical company GlaxoSmithKline (GSK) has pioneered a revolutionary new treatment that will cure the infection with a single dose.
Working in partnership with MMV, they have developed a drug known as tafenoquine (Kozenis®/Krintafel®), It is the first-ever antimalarial treatment to be delivered as a single dose for the prevention of relapse of P.vivax malaria, which looks set to combat the challenges posed by previous medicines and improve the process for patients.